Our Team

Andrew A. Parsons, Ph.D.

Vice President, Head of Preclinical Development

Dr. Parsons has led the Preclinical Development function in the ceedd since its creation. He was previously the Head of Preclinical Development for the Neurology and Gastrointestinal (NGI) Center of Excellence for Drug Discovery (CEDD) and a member of the Executive Leadership Team. Dr. Parsons joined SmithKline Beecham in 1991 as a lead biologist on the Migraine Program and played a key role in the identification of Frovatriptan and Tonabersat. He has worked in a number of therapy areas within Drug Discovery and has led teams that progressed numerous compounds in development. He was also previously the Chairman of the Imitrex (Sumatriptan) International Scientific Advisory Board. Dr. Parsons graduated with a B.S. and Ph.D. in pharmacology, University of Manchester, U.K. He worked as a post-doctoral researcher at the Institute of Physiology, University of Munich, Germany. He has authored more than 90 peer-reviewed publications.

• ‹‹ Previous
• Back to List
• Next ››